# Telmisartan for Treatment of COVID-19 Patients

> **NCT04355936** · PHASE4 · COMPLETED · sponsor: **Laboratorio Elea Phoenix S.A.** · enrollment: 400 (actual)

## Conditions studied

- COVID-19 Drug Treatment

## Interventions

- **DRUG:** Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.

## Key facts

- **NCT ID:** NCT04355936
- **Lead sponsor:** Laboratorio Elea Phoenix S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-19
- **Primary completion:** 2020-11-02
- **Final completion:** 2020-11-30
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2020-12-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04355936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04355936, "Telmisartan for Treatment of COVID-19 Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04355936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*